IT is well established that the volatile anesthetic sevoflurane in clinical useful concentrations depresses myocardial contractility in vitro because of a decrease in transsarcolemmal Ca 2ϩ influx. [1] [2] [3] [4] [5] [6] There is evidence that sevoflurane might also decrease Ca 2ϩ sensitivity of the contractile proteins, 7, 8 as was shown for halothane, enflurane, and isoflurane in skinned 9, 10 and intact muscle fibers. 11 The purpose of this study was to test the hypothesis that sevoflurane decreases myofibrillar Ca 2ϩ sensitivity in intact living cardiac fibers and to quantify the relative importance of changes in myofibrillar Ca 2ϩ sensitivity versus changes in myoplasmic Ca 2ϩ availability in the overall concentration-dependent negative inotropic effect of sevoflurane.
Materials and Methods
This study was approved by the Animal Care and Use Committee of the Mayo Foundation, Rochester, Minnesota, with protocols completed in accordance with National Institutes of Health guidelines and in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources Commission on Life Sciences, National Research Council). Adult male ferrets (weighing 1,100 -1,500 g and aged 16 -19 weeks) were anesthetized with sodium pentobarbital (100 mg/kg intraperitoneally), and the heart was quickly removed through a left thoracotomy. During generous superfusion with oxygenated physiologic solution (see below), suitable right ventricular papillary muscles were carefully excised from the beating heart. Papillary muscles were then mounted vertically in a temperature-controlled (30°C) muscle chamber that contains a physiologic salt solution made up in ultrapure water (Nanopure Infinity; Barnstead, Dubuque, IA) and with the following composition: Na ϩ 137.5 mM, K Experiments were conducted at 30°C and at a stimulus frequency of 0.25 Hz; isolated papillary muscle function is stable for many hours in these conditions. Suitable preparations were selected on the basis of the following criteria: length at which twitch active force is maximal (L max ) more than or equal to 3.5 mm, a mean cross-sectional area less than or equal to 1.2 mm 2 , and a ratio of resting to total force in an isometric twitch at L max less than or equal to 0.30. The tendinous end of each muscle was tied with a thin, braided polyester thread (size 6.0 Deknatel Surgical Suture, Fall River, ME) to the lever of a force-length servo transducer. 11 The ventricular end of each muscle was held in a miniature Lucite (Dupont, Wilmington, DE) clip with a built-in platinum punctate electrode; two platinum wires were arranged longitudinally, one along each side of the muscle, and served as anode during punctate stimulation. Rectangular pulses of 5-ms duration were delivered by a Grass S88D (Astro-Med, Inc., West Warwick, RI) stimulator at a stimulus interval of 4 s. Stimuli at 10 -20% above threshold (range, 4 -12 V) were used to minimize the release of endogenous norepinephrine by the driving stimuli. The muscles were stimulated and made to contract in alternating series of four isometric and four isotonic twitches at preload only during a 1-2-h period of stabilization.
At the end of the stabilization period, electrical stimulation was stopped, and multiple superficial cells were microinjected with the Ca 2ϩ -regulated photoprotein aequorin (Friday Harbor Laboratories, University of Washington, Friday Harbor, WA) to allow for subsequent detection of the intracellular Ca 2ϩ transient as previously described. 11 It was usually necessary to average luminescence and force signals of 64 -256 twitches to obtain a satisfactory signal-to-noise ratio in aequorin luminescence signals. For all muscles (n ϭ 32) combined, the peak aequorin signal was 10.18 Ϯ 9.99 (mean Ϯ SD) times the root mean square of the baseline "noise" value (range, 59.32-2.83).
We quantified peak systolic aequorin luminescence and time to peak aequorin luminescence. The decline of the aequorin signal was quantified by measuring the time from the stimulus to the time when aequorin luminescence had decreased to 25% of its peak value (t L25 ), and the slope of the logarithm of aequorin luminescence from 50% peak to 10% peak (k 50/10 ). The measurement of k 50/10 is based on the fact that the decline of the aequorin signals in isometric (but not isotonic 12 ) twitches follows an exponential decline, and that aequorin luminescence is approximately a 2.5 power function of [Ca 2ϩ ] i . The methods of delivery of sevoflurane were the same as for other volatile anesthetics. 13 In brief, oxygen flowed through the calibrated sevoflurane vaporizer and was allowed to mix in a 3-l reservoir bag. An occlusive roller pump (Masterflex; Cole-Parmer, Chicago, IL) delivered a continuous gas flow to the bubbler in the organ bath. The muscle chamber was covered with a tightly sealing Parafilm (American Can Company, Greenwich, CT) except for a narrow slit for the muscle clip and transducer hook. The concentration of sevoflurane was measured continuously between the reservoir bag and the roller pump with an anesthetic agent monitor (Ohmeda 5330, Madison, WI). Gas chromatography (HewlettPackard 5880A, Palo Alto, CA) measurements showed that 1% (vol/vol) sevoflurane corresponded to 0.18 mM in fluid at 30°C. The concentration of sevoflurane in fluid and the calculated partial pressure of sevoflurane in fluid followed closely imposed changes of anesthetic vapor concentration in the gas phase. After the sevoflurane administration was discontinued, its concentration in liquid declined rapidly and was always undetectable at 20 min.
Sevoflurane minimum alveolar concentration (MAC) in the ferret was calculated to be 2.7% (vol/vol) from the following data. The MAC values for isoflurane and halothane in the ferret are 1.52% and 1.01% (vol/vol). 14 The ratio of isoflurane MAC to halothane MAC in the ferret is 1.5, similar to that found in humans, dogs, and horses. 15 Sevoflurane MAC values for humans, dogs, and horses are 2.05, 2.36, and 2.31, respectively. 16 -18 The halothane MAC values for humans, dogs, and horses are reported to be 0.75, 0.86 and 0.88, respectively. 15 We calculated the MAC value for sevoflurane in the ferret assuming that the relative potency ratio of sevoflurane to halothane is close to that in humans (2.73), dogs (2.74), and horses (2.63) as well, which brings us to an estimated MAC of 2.7% (vol/vol) in the ferret used in this study.
All ferret papillary muscles were pretreated with bupranolol HCl 5 ϫ 10 Ϫ7 M before the onset of the experiment to abolish any ␤-adrenergic effects. All experiments were conducted with the initial muscle length set at L max .
Experimental Design
Two experimental protocols were used to examine the mechanism of the inotropic effect of sevoflurane. Each muscle served as its own control. Muscles contracted isometrically throughout the experiments.
In group 1 muscles (n ϭ 8), sevoflurane was applied in concentrations of 0.7%, 1.35%, 2.7%, and 4.05% (vol/vol). These concentrations correspond to 0.25, 0.5, 1.0, and 1.5 MAC in the ferret (see above). As soon as contractility had reached a steady state (which was usually the case after 10 -12 min of equilibration with a particular sevoflurane concentration), signals of force and aequorin luminescence were averaged on a digital storage oscilloscope (Nicolet 4094C, Madison, WI). Averaged signals were stored on 5.25-inch floppy disks and transferred to a desktop computer by software programs written in WFBASIC (Blue Feather Software, New Glarus, WI), which also measures all variables of contraction, relaxation, and aequorin luminescence. One to three records with 64 averaged twitches each were taken at control, at each sevoflurane concentration, and after sevoflurane washout, and were averaged to further improve signalto-noise ratio of the aequorin luminescence signals, if necessary, before quantification of variables. Variables of contraction and relaxation were determined from isometric twitches at the preload of L max : peak developed force, time to peak force, and time from peak force to half-isometric relaxation.
In group 2 muscles (n ϭ 24), we determined whether sevoflurane alters myofibrillar Ca 2ϩ sensitivity. After measurement of control variables of the isometric twitch, group 2a, 2b, and 2c muscles were exposed to 1.35% (0.5 MAC), 2.7% (1.0 MAC), or 4.05% (1.5 MAC) sevoflurane, respectively. When aequorin luminescence and peak isometric force had reached steady state, extracellular Ca 2ϩ was rapidly increased by adding small aliquots of a concentrated CaCl 2 solution (0.25 M) to the bathing solution, until the amplitude of peak developed force was equal to that in the control twitch. In three experiments, peak force slightly exceeded that of the control twitch after titration with CaCl 2 . In these instances, [Ca 2ϩ ] o was decreased by the addition of 10 -40 l of EGTA 0.2 M, pH 7.0, to precisely match peak force to that in the control twitch. Free [Ca 2ϩ ] o in the Ca 2ϩ back-titrated twitch was calculated with Fabiato's program. 19 Signals of force and aequorin luminescence were averaged and stored in the same way as in group 1. The protocol of Ca 2ϩ back-titration allowed us to compare aequorin luminescence signals in the absence (control) and presence of sevoflurane at equal peak developed force. If the magnitude of the intracellular Ca 2ϩ transient in the presence of sevoflurane (at equal peak force as in control) is different from that in the control twitch, there is likely to have been a change in myofibrillar Ca 2ϩ sensitivity.
Theoretical Analysis
To assess the relative effects of sevoflurane on intracellular Ca 2ϩ availability versus myofibrillar Ca 2ϩ sensitivity, the isometric Ca 2ϩ back-titration experiments were analyzed with the use of a multicompartment computer model 11 comprising the following compartments: free [Ca 2ϩ ] i , Ca 2ϩ bound to troponin C (TnC) and its force dependence, Ca 2ϩ bound to calmodulin, and sarcoplasmic reticulum (SR) Ca 2ϩ release and uptake. The model assumes that peak Ca 2ϩ occupancy of TnC is the same at equal developed force with or without sevoflurane. For the sake of simplicity, all sources of myoplasmic Ca 2ϩ delivery (transsarcolemmal Ca 2ϩ current, Na ϩ -Ca 2ϩ exchange, and SR Ca 2ϩ release) were lumped into one myoplasmic Ca 2ϩ delivery term (SR release) to gain one value, which is referred to as myoplasmic Ca 2ϩ availability. Myoplasmic Ca 2ϩ availability is expressed as percent of the value of the nonanesthetic control. Changes in myofibrillar Ca 2ϩ sensitivity were expressed as changes in off-rate of Ca 2ϩ from TnC at the Ca 2ϩ -specific site II (k off(TnC.Ca) ; the on-rate is very fast and limited only by diffusion), 20 with the understanding that various mechanisms can generate changes in Ca 2ϩ sensitivity (see Discussion). A detailed description of the analysis has been described elsewhere.
11 Myofibrillar Ca 2ϩ sensitivity was defined as 1/k off(TnC.Ca) and was expressed as percent of the value in the nonanesthetic control.
Statistical Analysis
Muscle characteristics between muscle groups were compared with one-way analysis of variance. Concentration-response relations between sevoflurane concentration and variables of contractility and aequorin luminescence were tested for differences with repeated-measures analysis of variance; pairwise comparisons versus control were conducted with Bonferroni-corrected paired t tests. In Ca 2ϩ back-titration experiments, aequorin luminescence in sevoflurane and high [Ca 2ϩ ] o were compared with control by the Student paired t test. Because absolute values of aequorin luminescence varied from muscle to muscle, percentage values of aequorin luminescence and relative changes are reported in which each muscle serves as its own control. 11 Relative changes in Ca 2ϩ sensitivity and availability derived at different sevoflurane concentrations were compared using one-way analysis of variance followed by pairwise comparison versus control with Bonferroni-corrected t test. Differences between relative values of Ca 2ϩ sensitivity and availability in a particular sevoflurane concentration were compared with the Student paired t test. Values were reported as mean Ϯ SD. Differences were considered significant at the P less than 0.05 level.
Results

Effects of Sevoflurane on Contractility and Intracellular Ca
2ϩ Transient Group 1 muscle characteristics in control conditions at L max are shown in table 1. Figure 1 illustrates a representative example of a concentration-response experi- L max ϭ length at which twitch active force is maximal; CSA ϭ cross-sectional area; R ϭ resting tension; T ϭ total tension.
ment to incremental concentrations of sevoflurane on aequorin luminescence and force in isometric twitches. Table 2 and figure 2 summarize the values of variables of contractility and of aequorin luminescence during control and cumulative concentration-response experiments to sevoflurane. Sevoflurane caused a concentration-dependent decrease of force and aequorin luminescence over the concentration range studied (figs. 1 and 2, left). Sevoflurane shortened the duration of the isometric twitch (time to peak force) and isometric relaxation half time in a concentration-dependent manner ( fig. 2, right) . Sevoflurane did not change time to peak light ( fig. 2 , right) and did not affect the decline of aequorin luminescence measured by t L25 and the slope k 50/10 of the logarithm of aequorin luminescence during decline from 50% to 10% of peak.
Effects of Sevoflurane on Myofibrillar Ca 2ϩ
Sensitivity There were no statistically significant differences for L max , mean cross-sectional area, resting force or preload at L max , total force, and the ratio of resting to total force among the three muscle groups 2a, 2b, and 2c used in this experimental protocol (table 1) . A typical Ca 2ϩ back-titration experiment is shown in figure 3 . Aequorin luminescence and isometric force were measured in control ( fig. 3, left) and during exposure to sevoflurane 2.7% (1 MAC; fig. 3 ] o values at the end of the procedure were 3.00 Ϯ 0.09, 3.70 Ϯ 0.29, and 4.59 Ϯ 0.42 mM in 0.5, 1.0, and 1.5 MAC sevoflurane, respectively. Figure 4 summarizes the results of the Ca 2ϩ back-titration experiments in each of three sevoflurane concentrations. Figure 5 shows a typical Ca 2ϩ back-titration experiment ( fig.5, top) and part of the analysis procedure (fig. 5, middle and bottom). First, aequorin luminescence signals that would match the amplitude and time course Values are mean Ϯ SD.
* P Ͻ 0.01, † P Ͻ 0.05, one-way repeated-measures analysis of variance followed by comparisons versus control by Bonferroni-corrected paired t tests. L max ϭ length at which twitch active force is maximal; k 50/10 ϭ slope of logarithm of aequorin luminescence from 50% peak to 10% peak by least-squares linear regression. ] o on myoplasmic delivery was found by searching the least squares fit to the experimentally measured aequorin luminescence signal ( fig. 5 , top, middle) by varying SR release only and using the k off(TnC.Ca) value found earlier for the aequorin luminescence signal in the back-titrated twitch. Figure 6 summarizes the analyses for all Ca 2ϩ backtitration experiments and shows the relative effects of sevoflurane on myoplasmic Ca 2ϩ availability and on myofibrillar Ca 2ϩ sensitivity. The results of the analysis are as follows: (1) sevoflurane decreases myoplasmic Ca 2ϩ availability in a concentration-dependent manner; (2) sevoflurane decreases myofibrillar sensitivity; (3) the decrease of myofibrillar Ca 2ϩ sensitivity is already fully present at 2.7% (vol/vol; 1 MAC) sevoflurane; and (4) sevoflurane decreases myoplasmic Ca 2ϩ availability and myofibrillar Ca 2ϩ sensitivity to the same relative extent, except at 4.05% (vol/vol; 1.5 MAC), where sevoflurane decreases Ca 2ϩ availability more than Ca 2ϩ sensitivity.
Discussion
Studies in isolated heart, intact cardiac muscle tissue preparations, and single ventricular myocytes demonstrated a concentration-dependent decrease of indices of contractility by sevoflurane in various species such as rat, dog, guinea pig, and humans. [1] [2] [3] [4] [5] [6] [21] [22] [23] [24] As for other volatile anesthetics, the negative inotropy of sevoflurane might be associated with (1) effects on transsarcolemmal Ca 2ϩ flux; (2) alteration of SR function; (3) a decrease of free intracellular [Ca 2ϩ ] level during systole; and (4) modification of the responsiveness of the contractile proteins to activation by Ca 2ϩ . The current study is the first to show the effects of sevoflurane on the intracellular Ca 2ϩ transient and to assess whether sevoflurane alters myofibrillar Ca 2ϩ sensitivity in intact ventricular myocardium. Measurements of free intracellular Ca 2ϩ , using the bioluminescent protein aequorin, and of contractile force show a concomitant concentration-dependent decrease in these variables, indicating that the negative inotropy of sevoflurane is related to a decreased intracellular Ca 2ϩ availability. Indeed, the negative inotropic effect of sevoflurane has been mainly attributed to depression of transsarcolemmal Ca 2ϩ influx, [1] [2] [3] [4] [5] whereas the effects of sevoflurane on the SR seem to be modest. 1, 2, 22 Sevoflurane interacts with the L-type Ca 2ϩ channel in cultured neonatal rat ventricular myocytes since the L-type Ca 2ϩ channel agonist Bay K 8644 significantly prevented the sevofluranedepressed contractile amplitude. 5 The sevoflurane-induced depression of myocardial contractility was accompanied by a shortening of duration of action potential in canine ventricular muscle strips and results from significant blockade of transsarcolemmal Ca 2ϩ current. 3, 4 In guinea pig papillary muscle, sevoflurane decreased contractile force and duration of action potential in a concentration-dependent fashion.
2 Sevoflurane depressed contractile force at rested state and at low stimulation frequencies, whereas it did not suppress potentiated state contractions and also depressed contractile force after ryanodine. 2 A comprehensive study on the mechanical and electrophysiologic effects of sevoflurane was conducted by Park et al. 1 In guinea pig myocardium, sevoflurane decreased maximum rate of force development at low stimulation rates but not at high stimulation rates. Sevoflurane decreased the initial rate of force development less than the rate of "late" force development, and selectively decreased late peak force in high K ϩ Tyrode solution without changing early peak force. Taken together, these observations led to the conclusion that sevoflurane has almost no effect on SR Ca 2ϩ release. Sevoflurane increased duration of action potential, decreased peak L-type Ca 2ϩ current, and suppressed the delayed K ϩ current, which appears to underlie the increased duration of action potential. and/or (7) possibly other mechanisms. The affinity of TnC for Ca 2ϩ is determined by the off-rate of TnC's Ca 2ϩ -specific binding site II, as the on-rate is very fast and only limited by diffusion. 20 Halothane did not change 27 or slightly increased the Ca 2ϩ affinity of isolated cardiac TnC in vitro 28 and decreased k off(TnC.Ca) in human recombinant cardiac TnC. 29 These effects cannot account for the decrease in myofibrillar Ca 2ϩ sensitivity by halothane. The effects of sevoflurane on Ca 2ϩ binding to TnC have not yet been investigated.
In rat skinned cardiac fibers, sevoflurane decreased the rate of force redevelopment after a release-stretch cycle (k tr ). 7 When interpreted in a two-state cross-bridge model, this finding suggests a decrease in the crossbridge apparent attachment rate (f app ) with no changes in the cross-bridge detachment rate (g app ). This would keep fewer cross-bridges in the force-generating state, so that less force is generated, even if the Ca 2ϩ transient were not changed. This would manifest itself as a decreased myofibrillar Ca 2ϩ sensitivity in intact fibers as observed in this study.
In intact cardiac muscle, there is indirect evidence for a decrease in myofibrillar Ca 2ϩ sensitivity by sevoflurane. 8 The negative inotropic effect of sevoflurane was more pronounced in isometric conditions, where the native myofibrillar Ca 2ϩ sensitivity is high, than in unloaded contractions, where the native myofibrillar Ca 2ϩ sensitivity is low. 8 Sevoflurane abbreviated both time to peak force and isometric relaxation half-time. The acceleration of isometric relaxation was not a consequence of the concomitant decrease in peak force, as isometric relaxation half-time was unchanged in control conditions over the range of extracellular Ca 2ϩ concentrations of 0.45-2.25 mM. 8 Isometric relaxation in cardiac muscle is controlled by the contractile proteins themselves, whereas cell relengthening rates in isolated myocytes availability to the same extent as isoflurane yet less than halothane (P Ͻ 0.01, one-way analysis of variance and Bonferroni-corrected t tests). Yet the decrease in myofibrillar Ca 2ϩ sensitivity was not concentration-dependent. Anesthetic-induced decreases in myofibrillar Ca 2ϩ sensitivity were already maximal at 0.5 MAC halothane and 1 MAC isoflurane and sevoflurane. This suggests a saturable process, the nature of which remains to be defined. In skinned rat cardiac fibers, 2 MAC sevoflurane decreased k tr and f app more than 1 MAC sevoflurane, observations that suggest a concentration-dependent effect. 7 Yet, because of the loss of certain natively present constituents and of membrane regulation of contractility, results obtained in skinned muscle fiber preparations are difficult to extrapolate to intact myocardium.
Halothane, isoflurane, 11 and sevoflurane (current study) at equipotent concentrations decreased Ca 2ϩ sensitivity in intact muscle to the relative same extent (oneway analysis of variance, P Ͼ 0.1). This is consistent with observations that there were no differences between effects of volatile anesthetics on pCa-force relations and maximal activated force in skinned rat cardiac fibers 9 and in human skinned cardiac fibers. 10 However, sevoflurane and halothane exerted differential effects on cross-bridge cycling parameters. Sevoflurane did not decrease the fraction of attached cross-bridges (␣ fs ) and g app , whereas halothane did. Sevoflurane 1 MAC decreased k tr and f app less than 1 MAC halothane, and 2 MAC sevoflurane decreased k tr and f app more than 2 MAC halothane. 7 Studies of cross-bridge kinetics have shown differences between anesthetics that were not resolved from examination of pCa-force relations of skinned fibers and from analysis of myofibrillar Ca 2ϩ sensitivity in intact fibers. Therefore, one might conclude that various sites of contractile proteins are affected by volatile anesthetics.
The results of this study must be interpreted in the context of the experimental conditions in which they were obtained. Results obtained here at 30°C and a stimulus interval of 4 s may differ from those that one could obtain at the more physiologic conditions of the animal, 37-38°C and 200 beats/min.
In summary, in intact ferret papillary muscle, the negative inotropic effect of sevoflurane is caused by a decrease of myoplasmic Ca 2ϩ availability and of myofibrillar Ca 2ϩ sensitivity in equal proportions, except at 1.5 MAC, where myoplasmic Ca 2ϩ availability decreases more. These changes are at the basis of the negative inotropic effect of sevoflurane in mammalian ventricular myocardium.
